The KRM Ayurveda Ltd IPO is one of the upcoming SME public issues in India’s capital markets. It offers investors an opportunity to participate in the Ayurveda and wellness services sector, including clinical operations, Ayurvedic product manufacturing and telemedicine services. Below is a complete investor-friendly overview of the IPO.
KRM Ayurveda IPO — covering all the points you listed: IPO dates, issue size, market lot & investment, company overview, products, financials, objectives, allotment & listing process, strengths, considerations, and weaknesses. All facts are sourced from public filings and IPO information as available.
📅 IPO Important Dates
Here are the key dates related to the KRM Ayurveda IPO:
| Event | Date |
|---|---|
| IPO Opening Date | 19 January 2026 |
| IPO Closing Date | 21 January 2026 |
| Basis of Allotment | 22 January 2026 |
| Refund Initiation | 23 January 2026 |
| Shares Credited to Demat | 23 January 2026 |
| Listing Date | 27 January 2026 |
The IPO is slated to be listed on the NSE SME platform
💰 Issue Size & Price Band
| Particulars | Details |
|---|---|
| Price Band | ₹128 – ₹135 per equity share |
| Face Value | ₹10 per share |
| Total Issue Size | ₹77.49 crore |
| Fresh Issue | 57,40,000 equity shares (entire issue) |
| Offer for Sale | Nil (100% fresh issue) |
| Issue Type | Book Building IPO |
The IPO comprises entirely of a fresh issue, with no shares being sold by existing shareholders.
📊 Market Lot Size & Investment Requirement
The minimum number of shares that an investor can apply for in the KRM Ayurveda IPO is fixed in specific lots. Investors are required to bid in multiples of the lot size as prescribed.
| Investor Category | Lot Size (Shares) | Approximate Investment (₹135 per share) |
|---|---|---|
| Retail Investor (Minimum) | 2,000 shares | ₹2,70,000 |
| Retail Investor (Maximum) | 2,000 shares | ₹2,70,000 |
| Small HNI (Minimum) | 3,000 shares | ₹4,05,000 |
| Small HNI (Maximum) | 7,000 shares | ₹9,45,000 |
| Big HNI (Minimum) | 8,000 shares | ₹10,80,000 |
The minimum bid for retail investors requires two lots of 1,000 shares each.
🏢 About the Company (About Share)
KRM Ayurveda Ltd is an Ayurvedic healthcare and wellness company incorporated in 2019. It operates a network of hospitals and clinics in India and provides telemedicine consulting services internationally. The company also manufactures a range of Ayurvedic products, herbal remedies and wellness items.
The promoters of the company include Mr. Puneet Dhawan and Mrs. Tanya Dhawan. The firm’s operations encompass both clinical care and product distribution, positioning it in the growing Ayurveda and wellness segment.
🧴 Key Products & Solutions
KRM Ayurveda’s portfolio includes:
- Ayurvedic medicines and formulations
- Herbal and botanical remedies
- Supplements and wellness products
- Pain relief oils and immunity boosters
- Telemedicine consultation services
- Hospital and clinic-based Ayurvedic treatments
These products and services are designed for general wellness, chronic disease management, immunity building, pain relief, and skin care.
📈 Financial Performance Snapshot
Below is a snapshot of recent key financials (in ₹ Crores):
| Financial Year | Total Income | Profit After Tax |
|---|---|---|
| 2023 | ₹89.29 | ₹7.60 |
| 2024 | ₹67.16 | ₹3.41 |
| 2025 | ₹76.55 | ₹12.10 |
The company has reported steady revenue and profit growth, with its PAT rising significantly in 2025
🎯 IPO Objectives (Use of Funds)
The company plans to utilise the IPO proceeds for several strategic objectives:
- Capital expenditure for the construction and development of telemedicine and operational facilities.
- Purchase of CRM software and technology infrastructure.
- Human resources expansion and training.
- Repayment or prepayment of borrowings.
- Working capital requirements to support business operations.
- General corporate purposes.
These objectives are aimed at expanding the company’s operations, enhancing technology capabilities and strengthening financial health.
🧾 Allotment & Listing Process
Once the subscription period ends:
- The Basis of Allotment will be finalised on 22 January 2026.
- Refunds (if any) will be initiated on 23 January 2026.
- Shares will be credited to Demat accounts on the same day.
- The shares are expected to be listed on NSE SME on 27 January 2026.
Investors can check the allotment status on the registrar’s website by using their application number or PAN.
⭐ IPO Review – Strengths & Considerations
✔ Strengths
- Well-defined offering with a price band appealing to SME investors.
- Operates both clinical healthcare facilities and product manufacturing.
- Growing income and profitability, with a notable increase in PAT in FY25.
- Provides telemedicine services, enabling reach beyond traditional locations.
- Experienced management and skilled workforce.
⚠ Considerations
- A significant portion of revenue is geographically concentrated in a few regions.
- High employee attrition has been reported, which could affect service delivery.
- Being an SME IPO, post-listing liquidity may be limited.
- Dependence on third-party payers and insurance reimbursements can impact cash flows. (The Financial Express)
❌ Weaknesses
- The company’s registered office and hospital premises are leased, which may cause relocation risks if leases are not renewed.
- Legal proceedings and consumer complaints could pose legal and operational challenges.
- Operations rely on government and third-party payers, making the business sensitive to policy changes and claim settlement issues. (The Financial Express)
- SME status can mean lower trading volumes and higher volatility after listing.
Disclaimer
The information shared here is intended solely for educational and general awareness purposes. Any securities, investments, or IPO-related details mentioned should not be interpreted as financial advice or investment recommendations. Readers are encouraged to conduct their own independent research or seek guidance from a qualified financial professional before making investment decisions.
IPO-related updates are provided for informational use only. Market trends, past performance, or investor interest do not ensure future outcomes. We are not registered with SEBI. Investments in IPOs and the securities market involve inherent risks, and individuals should carefully evaluate their financial situation or consult a certified financial advisor before investing.
